睿知中国医院研究地图
候选清单

邀请入组肺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07920822,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically diagnosed as advanced malignant solid tumor;

    入选标准第 5 条

  3. According to RECIST 1.1 standard, at least one measurable tumor lesion. For lesions that have received previous radiotherapy, the lesion can be included in the measurable lesion only when there is clear disease progression after radiotherapy;

    入选标准第 8 条

    Toxicity of previous anti-tumor treatment (such as previous chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has recovered to ≤ grade 1 level (except for hair loss);

    入选标准第 9 条

    Pregnant women of childbearing age need negative pregnancy test results. Subjects with reproductive capacity (and their partners) voluntarily use effective contraceptive methods during the treatment period and within 6 months after the last use of the investigational drug, such as condoms, oral or injectable contraceptives, etc.

    入选标准第 15 条

    Within the 3 months prior to the administration of 177Lu-HX02, the subject had received radiotherapy drugs, including but not limited to: lutetium-177, radium-223, etc.

    排除标准第 1 条

    Within the 4 weeks prior to the administration of 177Lu-HX02, the subject had undergone major surgery, chemotherapy, biological therapy, immunotherapy, endocrine therapy (except hormone replacement), large molecule targeted therapy or off-label drug treatment. Within the 2 weeks prior to administration, the subject had received local palliative radiotherapy, traditional Chinese medicine with anti-tumor indications, small molecule targeted drugs.

    排除标准第 2 条

    Within 2 weeks prior to the first administration of the study drug, the subject had received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), albumin infusion and renal replacement therapy.

    排除标准第 3 条

    Currently has active infection and requires systemic anti-infection treatment (such as acute bacterial infection, tuberculosis, active hepatitis B/ C, active syphilis, etc.). Active hepatitis B is defined as: HBsAg or HBcAb test result is positive or exceeds the normal reference range, accompanied by hepatitis B virus titer > 2500 copies/mL or 500 IU/mL (excluding subjects who received anti-hepatitis B virus treatment for at least 14 days, HBV-DNA降至≤ 2500 copies/mL or 500 IU/mL, and agreed to continue treatment during the study period); active hepatitis C is defined as: hepatitis C antibody positive or exceeds the normal reference range and HCV-RNA positive; syphilis-specific antibody positive; HIV antibody positive;

    排除标准第 10 条

    Within the 5 years prior to the administration of 177Lu-HX02, the subject had any other active malignant tumors (excluding surgically resected and non-recurrent skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical cancer or other in situ cancers);

    排除标准第 12 条

  4. ECOG score 0 to 1, able to tolerate PET/CT and SPECT/CT examinations;

    入选标准第 3 条

  5. Bone marrow Neutrophil count ≥ 1.5×109/L and white blood cell count ≥ 2.5×109/L; Platelets ≥ 100×109/L; Hemoglobin ≥ 90 g/L;

    入选标准第 11 条

    Liver function Total bilirubin ≤ 1.5×ULN (for liver metastasis subjects, total bilirubin ≤ 2×ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3×ULN (for liver metastasis subjects, ALT and AST < 5×ULN); Albumin > 30 g/L;

    入选标准第 12 条

    Renal function Serum creatinine ≤ 1.5×ULN and creatinine clearance rate ≥ 50 mL/min;

    入选标准第 13 条

    Coagulation function International normalized ratio (INR) ≤ 2.0, activated partial thromboplastin time (APTT) ≤ 1.5×ULN. Exception: Subjects receiving warfarin anticoagulation therapy can have INR 2 to ≤ 3;

    入选标准第 14 条

  6. 68Ga-HX01 PET/CT imaging positive. Defined as at least one lesion in the 68Ga-HX01 PET/CT imaging having SUVmax ≥ 3.0 or tumor-to-liver ratio (SUVmax/SUVmean) (T/L ratio) > 1;

    入选标准第 7 条

    The medical history, computed tomography (CT) or magnetic resonance imaging (MRI) examination indicated the presence of central nervous system (CNS) metastatic lesions. Excluding: CNS metastatic lesions that have undergone radiotherapy or surgery, the subject did not use corticosteroids, anticonvulsants, or diuretics to control symptoms within 2 weeks prior to the first administration, the imaging indicated no progression or new onset of brain lesions, and there were no neurological symptoms.

    排除标准第 4 条

  7. Pregnant women;

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07920822,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Have a thorough understanding of this study and have voluntarily signed the informed consent form;
  2. Age 18 to 75 years old, gender not restricted;
  3. ECOG score 0 to 1, able to tolerate PET/CT and SPECT/CT examinations;
  4. Expected survival period ≥ 6 months;
  5. Histologically or cytologically diagnosed as advanced malignant solid tumor;
  6. Previous standard treatment failed;
  7. 68Ga-HX01 PET/CT imaging positive. Defined as at least one lesion in the 68Ga-HX01 PET/CT imaging having SUVmax ≥ 3.0 or tumor-to-liver ratio (SUVmax/SUVmean) (T/L ratio) > 1;
  8. According to RECIST 1.1 standard, at least one measurable tumor lesion. For lesions that have received previous radiotherapy, the lesion can be included in the measurable lesion only when there is clear disease progression after radiotherapy;
  9. Toxicity of previous anti-tumor treatment (such as previous chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has recovered to ≤ grade 1 level (except for hair loss);
  10. The functional level of organs must meet the following requirements:
  11. Bone marrow Neutrophil count ≥ 1.5×109/L and white blood cell count ≥ 2.5×109/L; Platelets ≥ 100×109/L; Hemoglobin ≥ 90 g/L;
  12. Liver function Total bilirubin ≤ 1.5×ULN (for liver metastasis subjects, total bilirubin ≤ 2×ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3×ULN (for liver metastasis subjects, ALT and AST < 5×ULN); Albumin > 30 g/L;
  13. Renal function Serum creatinine ≤ 1.5×ULN and creatinine clearance rate ≥ 50 mL/min;
  14. Coagulation function International normalized ratio (INR) ≤ 2.0, activated partial thromboplastin time (APTT) ≤ 1.5×ULN. Exception: Subjects receiving warfarin anticoagulation therapy can have INR 2 to ≤ 3;
  15. Pregnant women of childbearing age need negative pregnancy test results. Subjects with reproductive capacity (and their partners) voluntarily use effective contraceptive methods during the treatment period and within 6 months after the last use of the investigational drug, such as condoms, oral or injectable contraceptives, etc.

排除标准:Exclusion Criteria:

  1. Within the 3 months prior to the administration of 177Lu-HX02, the subject had received radiotherapy drugs, including but not limited to: lutetium-177, radium-223, etc.
  2. Within the 4 weeks prior to the administration of 177Lu-HX02, the subject had undergone major surgery, chemotherapy, biological therapy, immunotherapy, endocrine therapy (except hormone replacement), large molecule targeted therapy or off-label drug treatment. Within the 2 weeks prior to administration, the subject had received local palliative radiotherapy, traditional Chinese medicine with anti-tumor indications, small molecule targeted drugs.
  3. Within 2 weeks prior to the first administration of the study drug, the subject had received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), albumin infusion and renal replacement therapy.
  4. The medical history, computed tomography (CT) or magnetic resonance imaging (MRI) examination indicated the presence of central nervous system (CNS) metastatic lesions. Excluding: CNS metastatic lesions that have undergone radiotherapy or surgery, the subject did not use corticosteroids, anticonvulsants, or diuretics to control symptoms within 2 weeks prior to the first administration, the imaging indicated no progression or new onset of brain lesions, and there were no neurological symptoms.
  5. Suffering from severe cardiovascular diseases, including but not limited to the following conditions:
  6. Within 6 months prior to administration, suffered from acute myocardial infarction, unstable angina pectoris, or received coronary angioplasty or stent;
  7. New York Heart Association class II to IV congestive heart failure or left ventricular ejection fraction (LVEF) < 50% or within the lower limit of the normal range;
  8. Uncontrolled hypertension (even with optimal treatment, with systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
  9. Baseline electrocardiogram QTcF interval prolonged (> 480 ms);
  10. Currently has active infection and requires systemic anti-infection treatment (such as acute bacterial infection, tuberculosis, active hepatitis B/ C, active syphilis, etc.). Active hepatitis B is defined as: HBsAg or HBcAb test result is positive or exceeds the normal reference range, accompanied by hepatitis B virus titer > 2500 copies/mL or 500 IU/mL (excluding subjects who received anti-hepatitis B virus treatment for at least 14 days, HBV-DNA降至≤ 2500 copies/mL or 500 IU/mL, and agreed to continue treatment during the study period); active hepatitis C is defined as: hepatitis C antibody positive or exceeds the normal reference range and HCV-RNA positive; syphilis-specific antibody positive; HIV antibody positive;
  11. Non-infectious pneumonia requiring hormone treatment and radiation pneumonitis, hemodynamic-altering thrombotic events, active bleeding events or other serious complications;
  12. Within the 5 years prior to the administration of 177Lu-HX02, the subject had any other active malignant tumors (excluding surgically resected and non-recurrent skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical cancer or other in situ cancers);
  13. Known to be allergic to the components of the study drug or its analogues;
  14. Any person with difficulty in urination or urinary incontinence;
  15. Suffering from claustrophobia or other conditions that prevent cooperation in PET/CT or SPECT/CT examinations;
  16. Patients with mental disorders such as depression, schizophrenia, delusion, hallucination or suicidal ideation;
  17. Pregnant women;
  18. Other situations that the investigator considers the subject is not suitable to participate in this study.

引自 ClinicalTrials.gov, NCT07920822, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07920822,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07920822